The DNMT3B C→T promoter polymorphism and risk of breast cancer in a British population: a case-control study

Breast Cancer Research

Table 1 DNMT3B genotype frequencies of breast cancer cases and controls

Group	No. of subjects	TT No. (%)	TC No. (%)	P ^a	OR (95% CI)	CC No. (%)	P ^a	OR (95% CI)	TC+CC No. (%)	P ^a	(OR, 95% CI)
Control	258	60 (23.3)	116 (45.0)			82 (31.8)			198 (76.8)
All breast cancer	352	59 (16.8)	173 (49.1)	0.06	1.52 (0.99–2.33)	120 (34.1)	0.10	1.49 (0.94–2.35)	293 (83.2)	0.05	1.51 (1.01–2.25)
Under 40^b	212	34 (16.0)	103 (48.6)	0.08	1.57 (0.95–2.58)	75 (35.4)	0.09	1.61 (0.96–2.73)	178 (84.0)	0.06	1.21 (1.01–1.45)
Family history bilateral cancer^c	245	46 (18.5)	119 (47.8)	0.24	1.34 (0.84–2.12)	84 (33.7)	0.26	1.34 (0.82–2.18)	203 (81.5)	0.19	1.34 (0.87–2.06)

OR, odds ratio; CI, 95% confidence interval. ^a P was determined by Fisher's exact test (two-sided) for the relevant genotype, with the TT homozygotes as reference. ^bThis group includes cases that were originally selected on the basis of family history but where the diagnosis was made earlier than 40 years of age. ^cThis group includes cases that were originally selected on the basis of diagnosis earlier than 40 years of age but where there was also bilateral disease or a family history of cancer.

ISSN: 1465-542X